Margin collapse in soft quarter; backward integration bet intact but timing uncertain

Delivered 1,006 MW; 32% YoY growth confirmed. But volume growth masks margin collapse.

Delivered ₹1,563.1 Cr, up 37.9% YoY. Claim of 38% matches delivered result.

Q1 EBITDA 8.1%, well below historical 12-16% range. Backward integration thesis unproven; commissioning Q4 FY27 still 8+ months away.

₹1.86/Wp cost rise. War-driven metal/EVA inflation is real but non-DCR oversupply prevents pass-through on BORM (35-47% of cost). Structural, not just transitory.

Only 76 MW DCR in Q1 (7.5% of 1,006 MW volume). Management expects 2-2.5x quarterly growth, but base is too small to materially impact FY27 EBITDA yet.

Prior FY27 guide: ₹1,500-1,600 Cr EBITDA. Q1 delivered ₹126 Cr (8.1%), annualizes to ~₹504 Cr. Management deferred guidance to H1; no revised target given. Implicit 60%+ cut vs prior.

Called 76 MW DCR in Q1 vs 1,006 MW total = 7.5%. Expected to grow 2-2.5x quarterly, but base too small to move needle in FY27. Margin benefit pushed to FY28.

88% of order book has escalation clauses, but only for cell costs. BORM (35% metals, 12% EVA, freight) cannot be passed due to oversupply. ₹1.86/Wp cost rise is structural this quarter.

Wafer-ingot capacity increased 6 GW → 9 GW; cell plant on track Q4 FY27 (prior was Dec → March). Module facility (Gangaikondan) first unit on June 29 per promise. Execution discipline maintained.

7.9 GW order book now includes larger mid-market, distribution channels (119+ distributors, 757 dealers). Pricing ₹0.50-1.50/Wp premium over large accounts. Mix benefit emerging but unproven at scale.

MSA escalation clauses cover only cell costs, not BORM (balance of raw materials). Metals, EVA, freight inflation in BORM was not passed due to competition. Even cell cost escalation was partially absorbed due to oversupply.

DCR delivers more margin than non-DCR. Cannot quantify separately yet due to small Q1 sample. Serious volumes will flow in coming quarters, allowing better clarity.

Capacity of 15.5 GW can deliver 9-9.5 GW for full year. Exact executability depends on customer decisions around ALMM 2 and infrastructure clarity. Allow one more quarter for clarity.

Captive cell ramp focus. Peers with in-house cells benefit from cell margins. We don't have cells until Q4 FY27. Strategy shift to retail channels carries temporary margin pressure.

Once cell line commissioned, margins will expand because DCR captures cell margins. True peer comparison only possible then. Different players at different cell commissioning stages.

Our cell lines are best-in-class, so cost will be among India's best. Chinese cells 4 cents/W landed price + 27.5% BCD = ~5.1 cents/W procurement cost. DCR pricing very different from non-DCR.

Let us reconnect in mid-year with clarity on DCR pricing, distribution penetration, and ALMM 2 policy. Margins broadly in this range but could improve.

Policy changes made customers tentative. Grandfathered projects facing price volatility and infrastructure delays. Not updating guidance now; waiting for clarity to emerge.

Four pillars: (1) Best-in-class products (20-year legacy), (2) Integrated world-class manufacturing (cell, wafer, module at Gangaikondan), (3) Cost-efficient structure, (4) Diversified customer base (large, mid-market, distribution). This mix will set us apart.

Grandfather projects: ~80 GW for non-DCR. ALMM 2 extension now allows C&I to also shift to non-DCR, topping up eligible volume. C&I market is 15 GW/year; 6-7 GW rooftop, rest ground-mount open access.

15.5 GW total capacity (Gangaikondan 6 GW module fully operational Q2; Vallam legacy + ramp). Actual volume depends on order book timing and customer decision-making around ALMM 2 / infrastructure clarity.

Fresh utility tenders post-Aug 2025 threshold total 35-40 GW, but execution 18-24 months out. H1 FY28 procurement expected.

Prior FY27 guidance ₹1,500-1,600 Cr EBITDA is implicitly cut. Q1 run-rate (~₹504 Cr) 66% below prior. Margin recovery dependent on DCR ramp, cost normalization, and capex margins.

Cost pressures (metals, EVA) continuing. DCR mix to grow 2-2.5x quarterly starting Q2, but small base limits impact. Management expects 'rationalization' in non-DCR margins if war-driven costs ease.

No specific margin target given. Backward integration margin benefit unproven; depends on cell cost competitiveness vs ₹4 cents/W Chinese import + 27.5% BCD.

₹500 Cr deployed in Q1 FY27. Full capex plan: 6 GW module facility ₹fully funded, 9 GW cell plant ₹~3,000 Cr, 9 GW wafer-ingot ₹5,600 Cr (phased), 15 GWh BESS ₹700-800 Cr (2-year build, phase 1 assembly Q1 FY28, cell Q4 FY29).

No debt drawn yet; drawdown sequenced to project milestones. Financial closure for debt in process. Capex will be major debt-funded (₹7-7.5 Cr over 2 years).

210 GW national capacity, 45-50 GW demand; 88% of order book MSAs only escalate cell, not BORM (35% metals, 12% EVA). War-driven inflation unpassable. Q1 margin 8.1% vs historical 12-16%; recovery path uncertain.

ALMM 2 cell mandate implemented June 1, deferred July 18 to Dec 31. Customers held procurement pending clarity. Further deferrals possible if cell capacity lags targets. C&I segment (15 GW/year) still uncertain on DCR vs non-DCR mix (estimate reduced 20-25 GW to 17 GW DCR).

₹10,000 Cr capex over FY27-28 on integrated platform (cell, wafer-ingot, BESS). Cell plant Q4 FY27 on track; wafer-ingot ground-breaking next month. Modular design allows phasing, but supply chain delays (equipment, labor) or policy shifts could push timelines and cost overruns.

Q1 DCR volume only 76 MW (7.5% of 1,006 MW total). Management expects 2-2.5x quarterly growth, but base is small and ramp depends on distribution network adoption, policy stability, and pricing discipline. No large-account DCR orders placed yet (management deferring to post-cell commissioning).

Large utilities and IPPs citing land acquisition, evacuation clearance, and utility infrastructure challenges as reasons for procurement delays. Grandfather non-DCR projects (80 GW) moving slower than expected. ALMM 2 policy volatility adding to wait-and-see posture.